JP4546454B2 - Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド - Google Patents

Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド Download PDF

Info

Publication number
JP4546454B2
JP4546454B2 JP2006503098A JP2006503098A JP4546454B2 JP 4546454 B2 JP4546454 B2 JP 4546454B2 JP 2006503098 A JP2006503098 A JP 2006503098A JP 2006503098 A JP2006503098 A JP 2006503098A JP 4546454 B2 JP4546454 B2 JP 4546454B2
Authority
JP
Japan
Prior art keywords
hif
oligonucleotide
cells
oligonucleotides
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006503098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006520195A (ja
JP2006520195A5 (enExample
Inventor
ヘジョン・ヨン
マオ・リンジュン
リー・ヨンボク
チャン−ホ・アン
ジャン・シャオミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rexahn Corp
Original Assignee
Rexahn Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Corp filed Critical Rexahn Corp
Publication of JP2006520195A publication Critical patent/JP2006520195A/ja
Publication of JP2006520195A5 publication Critical patent/JP2006520195A5/ja
Application granted granted Critical
Publication of JP4546454B2 publication Critical patent/JP4546454B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006503098A 2003-01-28 2004-01-28 Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド Expired - Fee Related JP4546454B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76618503A 2003-01-28 2003-01-28
US44436703P 2003-01-31 2003-01-31
PCT/US2004/002344 WO2004066949A2 (en) 2003-01-28 2004-01-28 Antisense oligonucleotides that inhibit expression of hif-1

Publications (3)

Publication Number Publication Date
JP2006520195A JP2006520195A (ja) 2006-09-07
JP2006520195A5 JP2006520195A5 (enExample) 2007-03-15
JP4546454B2 true JP4546454B2 (ja) 2010-09-15

Family

ID=32829853

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503098A Expired - Fee Related JP4546454B2 (ja) 2003-01-28 2004-01-28 Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド

Country Status (3)

Country Link
JP (1) JP4546454B2 (enExample)
AU (1) AU2004207576B8 (enExample)
WO (1) WO2004066949A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011353283A1 (en) 2010-12-30 2013-07-18 Samyang Biopharmaceuticals Corporation siRNA for inhibition of Hif1alpha expression and anticancer composition containing the same
US10307490B2 (en) * 2012-05-23 2019-06-04 The Ohio State University Lipid nanoparticle compositions for antisense oligonucleotides delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
WO2000076497A1 (en) * 1999-06-14 2000-12-21 Cancer Research Ventures Limited Cancer therapy
US7105656B2 (en) * 2000-10-26 2006-09-12 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
HUE037352T2 (hu) * 2002-04-05 2018-08-28 Roche Innovation Ct Copenhagen As A HIF-1alfa expresszálódását módosító oligomer vegyületek
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression

Also Published As

Publication number Publication date
WO2004066949A3 (en) 2005-12-01
AU2004207576A1 (en) 2004-08-12
JP2006520195A (ja) 2006-09-07
AU2004207576B8 (en) 2008-11-20
AU2004207576B2 (en) 2008-10-23
WO2004066949A8 (en) 2004-11-11
WO2004066949A2 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
US7235534B2 (en) Antisense strategy to modulate estrogen receptor response (ER α and/or ER β )
KR101749352B1 (ko) Ｓｉｒｔ1에 대한 천연 안티센스 전사체의 억제에 의해 ｓｉｒｔ1 관련된 질환의 치료
CN1656222B (zh) 反义iap核碱基寡聚物及其应用
KR102825946B1 (ko) IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료
JP2015518714A (ja) 遺伝子発現を調節するための組成物及び方法
KR20120118004A (ko) 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료
JP2025100705A (ja) Ｄｕｘ４の発現を調節するための化合物、方法及び医薬組成物
JP4429906B2 (ja) Ａｋｔ−１の発現を抑制するためのアンチセンスオリゴヌクレオチドの使用
EP1601325B1 (en) Antisense oligonucleotides that inhibit expression of hif-1
JP4546454B2 (ja) Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド
CN113897358A (zh) 靶向ensg00000203930基因的反义寡核苷酸及其应用
JP2009516710A (ja) ｅＩＦ４Ｅ−ＢＰ２の発現のモジュレート
US20250066793A1 (en) Anti-sense oligonucleotides and uses thereof
JP2013039036A (ja) ＨＩＦ−２αの発現を抑制する核酸
WO2024123799A9 (en) Inhibitory nucleic acids and methods of use thereof
CN121127248A (zh) 用于抑制线粒体偕胺肟还原组分1 (MARC1)表达的RNAi剂、其药用组合物及使用方法
US10443057B2 (en) Multi-targets interfering RNA molecules and their applications
CA2534996A1 (en) The use of sirna silencing in the prevention of metastasis
CA2321189A1 (en) Antisense oligonucleotides directed toward mammalian vegf receptor genes and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070123

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100301

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100401

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100506

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100601

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100701

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130709

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees